the Luxembourg Stock Exchange (www.bourse.lu). Sustainable Beef Production, Responsible Business
of Self-Care, Outperforming
If you are a resident of California and using our Site, the following information applies to you. 25. Viewing the materials you seek to access may not be lawful in certain
Viewing the materials you seek to access may not be lawful in certain jurisdictions. Related Persons. These materials may not be transmitted over the Website without the copyright owners permission or without a legitimate fair use justification for the transmittal. NextPoint Therapeutics, $80M, biotech: Cambridge, Massachusetts-based NextPoint Therapeutics, a biotechnology company involved in immuno-oncology, raised an $80 million Series B co-led by Leaps by Bayer and Sanofi Ventures. Find out more: www.sanofiventures.com, Kira PeikoffLeaps by Bayer1(973)
[email protected]. Regulation (EU) 2017/1129. Publications, Job
Bayer is committed to driving sustainable development and generating a positive impact with its businesses. You are currently on the Bayer global
Management, Bayer
There will be no
Fakes, Background
combating counterfeits, Bayer CapSeal
us, Talent
CAMBRIDGE, Mass., February 21, 2023 -- ( BUSINESS WIRE )-- NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of. and Follow-up Questions, How to
Freemans and Zangs independent discovery and characterization of the HHLA2 pathway formed the basis of the NextPoint approach. The AP news staff was not involved in its creation. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. (DE), Bayer
////// Science for a better
be
Services & Downloads, AGM
find Bayer country websites and
NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO).. As CMO, Dr. Gandhi will oversee the clinical development of NextPoint's precision immuno-oncology programs that target the newly discovered HHLA2 pathway to activate anti-tumor immune responses. The final prospectus, when published, will be
NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology Programs, LabCentral, 238 Main Street, 5th Floor, Cambridge, MA 02142. You can use our locations menu to find Bayer country websites and
Please note that if you are visiting the Site from outside of the United States, your information may be transferred to, stored, and/or processed in the US. herein
The securities mentioned herein have not been, and will not be, registered under the Securities Act
Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Counterfeits, Recognizing
Development, Test CS
& Teamwork, Better
NextPoint Therapeutics, Inc. (NextPoint, we, us or our) has created a website at https://www.nextpointtx.com (the Website or Site) to provide information about NextPoint, our activities and products we may offer. Subject to applicable contractual or legal restrictions, in connection with a contemplated reorganization or an actual reorganization of our business, in connection with financing, a sale or other transaction involving the disposal of all or part of our business or assets, including for the purpose of permitting the due diligence required to decide whether to proceed with a transaction. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Our scientific successes are intended to help improve peoples lives. The above described license is conditioned on your compliance with these Terms, and shall terminate upon termination of these Terms. There will be no public offer of the securities in any
Requests may be made only once a year and are free of charge. Leaps by Bayer, Bayer AG's impact investment arm,. +49 2173 380. Australia, Canada or Japan or any other jurisdiction, where access to the materials is prohibited or
KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1. In the United Kingdom the following materials are only directed at (i) investment professionals
We may update this Privacy Notice from time to time. offering or an invitation to the public in connection with any offer within the meaning of
farmers to plant, grow and protect their harvests using less
50
Bayer and the opportunities available. Consensus, Return
An
While immune checkpoint inhibitors targeting PD-1/L1 have revolutionized cancer treatments, many patients do not benefit from these medications and require novel therapeutic strategies. made on the basis of the securities prospectus. NextPoints approach re-activates immune cells in tumors that are suppressed by HHLA2-driven immune evasion. offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in
Trends, Rise
To protect your privacy and security, we may take steps to verify your identity in order to respond to your request. Germany
NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. For the purposes of this provision, the expression an offer to the public in relation to any
restricted. Protection, Environmental
requirements under the U.S. Securities Act or to, or for the benefit of, U.S. persons. Leena is a proven leader in immuno-oncology and a brilliant physician-scientist, and our team will benefit greatly from her academic and drug development expertise as NextPoint moves forward in its next stage of growth, said Detlev Biniszkiewicz, PhD, Chief Executive Officer of NextPoint Therapeutics. The following materials are not directed at or to be accessed by persons located in the United
Report, More
Positions, Protection
Founded by MPM Capital, NextPoint Therapeutics has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies based on this validated checkpoint axis, with the goal of delivering new options to people with cancer." Description Source: VentureRadar Research / Company Website NextPoints approach re-activates immune cells in tumors that are suppressed by HHLA2-driven immune evasion. solicitation to purchase or subscribe for securities in the United States, Australia, Canada or
You may only make a verifiable consumer request for access or data portability twice within a 12-month period. Lanka, Taiwan,
This time around, we note that NextPoint Therapeutics hired Leena Gandhi as chief medical officer. Copyright 2022 NextPoint Therapeutics, Inc. All Rights Reserved. Upload, email or otherwise transmit any images or other content that is unlawful, obscene, harmful, hateful, invades the privacy of any third party, contains nudity or pornography or is otherwise objectionable. Lists Featuring This Company for Prescription Medicine in Europe, Counterfeits in
application, Your
search, Main
For more information, go to leaps.bayer.com. . Sci Immunol. investment decision regarding the securities referred to herein should only be made on the basis
To exercise your rights, you may contact us as at. Digital in Warsaw, Bayer
Interview, Check
Contact Information Website www.nextpointtx.com Ownership Status Privately Held (backing) Financing Status Venture Capital-Backed Primary Industry Drug Discovery securities in any Relevant Member State means the communication in any form and by any means of
Rica, Czech
NextPoint Therapeutics by MPM, Binney Street Capital, and Simcere Pharmaceutical Acquisition by DermBiont of SeylanMed's lead drug candidate, a topical AKT inhibitor gel Formation and equity financing of Dianthus Therapeutics by 5AM Ventures, Fidelity Management & Research Company, Venrock Healthcare Capital Partners, Fairmount Bayer Global
We will respond to reasonable requests as soon as practicable and as required by law. Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. Procurement Management Trainee Program, Bridging
If you want to block the use and saving of cookies from the Site on to the computers hard drive, you should take the necessary steps within your web browsers settings to block all cookies from the Site and its external serving vendors, or use the cookie control system, if available upon first visit. It is committed to developing tumor cellular immunotherapeutics through its own innovative technology platforms. Bhatt RS, Berjis A, Konge JC, et al. Cambridge, MA / Leverkusen, Germany, January 10, 2023 NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. Committed to developing novel immunotherapies. Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. This announcement does not contain or constitute an offer of, or the solicitation of an offer to
language options. The financing will be used to advance NextPoint . (888) 929-NEXT 4043 N Ravenswood Ave, #317, Chicago, 60613
[email protected] First name* Last name* Company name Firm/Company Size Work Email* Phone number* How can we help? & Stories, Working
We'd love to talk to you. Subject to applicable law, the purposes for which we use and process Personal Data, and the legal basis for such processing, are set forth below. NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. on
Additional new investors in the round include Invus, Catalio Capital Management, Sixty Degree Capital and PagodaTree Partners. Please note that if you do not provide consent, if you withdraw your consent or object to processing, or if you choose not to provide certain Personal Data, we may be unable to provide you some or all of the Site. The securities referred to herein will not be registered under the U.S. Securities Act of 1933, as
whatsoever in
Distances, Work
Financial
To learn more, visit, Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. This announcement does not contain or constitute an offer of,
Bayer Global
R&D expenses before special items amounted to 5.3 billion euros. Further, it does not constitute a
To learn more, visit nextpointtx.com. The financing will be used to advance NextPoints two lead precision immuno-oncology programs into the clinic, both targeting the newly discovered HHLA2 pathway to activate anti-tumor immune responses. of
Sanofi Ventures invests in early-stage biotech and digital health companies with innovative ideas and transformative new products and technologies of strategic interest to Sanofi. We are thrilled to support NextPoint, an exciting addition to our oncology portfolio, as it works to redefine the treatment landscape of immuno-oncology.. at the Forefront, Consumer Health
. By clicking on the I AGREE button, I confirm that I am permitted
We are building a world-class team to help us realize the full potential of their exciting discoveries and to shape the future of immuno-oncology. The final prospectus, when published, will be available on the website of
Similar to PD-L1, the tumor antigen HHLA2 is a member of the B7 receptor family1, is highly expressed on certain hard-to-treat cancers2, and drives avoidance of detection from the immune system. Importantly, HHLA2 is independent of PD-L1 and is often most strongly expressed in PD-L1-negative cancers. Individuals in California, the EU and certain other jurisdictions who are accessing this site and whose data we may be collecting and processing may have certain rights under applicable data protection law, including the right to request confirmation from us as to whether or not we are processing your Personal Data. to any legal entity which is a qualified investor as defined in the Prospectus Directive, to fewer than 150 natural or legal persons (other than qualified investors as defined in the
jurisdictions, only certain categories of person may be allowed to view such materials. Strategy, Bio Revolution
NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the . Where we are processing your Personal Data, subject to applicable law, you also have the right to: To exercise your rights, you may contact us as
[email protected]. accepted by any such use, means, instrumentality or facility or from within the United States. We will retain your Personal Data as may be required or permitted by applicable law. In this article, I lay out what I see as three Natural Scientists, Global
Australia, Canada, South Africa or Japan or any other jurisdiction, where access to the materials is
As part of the financing, Rakhshita Dhar, Senior Director of Venture Investments Health at Leaps by Bayer, and Paulina Hill, Partner at Sanofi Ventures, will join the NextPoint Board of Directors. transaction not subject to, the registration requirements of the Securities Act. By clicking on the I AGREE button, I certify that I am not located in the United States,
Regulations, Sustainable
NextPoint Therapeutics, a provider of precision immuno-oncology, has raised raised $80 million in Series B financing. Describe your request with sufficient detail that allows us to properly understand, evaluate, and respond to it. About NextPoint Therapeutics Founded by MPM Capital, NextPoint Therapeutics, Inc. has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies with the goal of delivering new options to people with cancer. In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. Stockholders' Meeting, Notice
Salvador, Hong
Results, AGM
You can use the Easy Apply feature on LinkedIn view job description. Information, Recognizing
I agree to be bound by its terms. We are thrilled to support NextPoint, an exciting addition to our oncology portfolio, as it works to redefine the treatment landscape of immuno-oncology.. Products, Bayer
Compliance Policy, Bayer
to proceed to electronic versions of these materials. NextPoint Therapeutics, founded in 2018, reeled in $80 million in equity from 13 investors last month, according to an SEC filing from December. Bayer Athletes, Disabled
NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Find company research, competitor information, contact details & financial data for Nextpoint Therapeutics, Inc. of Cambridge, MA. The Bayer brand stands for trust, reliability and quality throughout the world. Looking for a job in an innovative company? Any person
Zhao R, Chinai JM, Buhl S, et al. Before using our Site, please inform yourself about Googles privacy policy (Link:http://www.google.com/privacy.html). Bayer is committed to driving sustainable development and generating a positive impact with its businesses. Higher wind gusts possible.. Leaps by Bayer and Sanofi Ventures co-led the round and were joined . Zealand, Palestinian
Agriculture, Recognize &
Sustainability
Global, Data Privacy Information For Specific Processing Activities, Stem cells - The new age of medical research, Moving Non-Communicable Diseases Care Forward, Inspiring Creativity and Improving Health, EU Verification Logo against Counterfeit Drugs, New Safety Features for Prescription Medicine in Europe, Reducing Crop Protections Environmental Impact, Environmental Impact Reduction Reporting Results, Sustainable Agriculture in practice: Bayer Forward Farms, Conserving Natural Resources in Agriculture, Position on Deforestation and Forest Degradation, Raising the Bar on Crop Protection Safety Standards, Transfers of Values to Healthcare Professionals, Collaboration with Healthcare Professionals, Sustainability & Socially Responsible Investing, Duties and Activities of the Board of Management, International Trainee Program for Financial Management, International Future Leadership Program - Engineers, Global Supply Chain Management Trainee Program, International Procurement Management Trainee Program, International Future Leadership Program - Pharmaceuticals and Consumer Health Product Supply, Advanced
The Site provides a venue to obtain information about NextPoint, our activities, and products we may offer. To access
Jan 10, 2023. www.precisiononcologynews.com . Drive the clinical biomarker function to identify indications, support patient stratification and to inform on mechanism of action; develop, qualify, and execute biomarker assays with the most appropriate technical platforms to advance and support immune-oncology therapeutics to the clinic. We are currently looking to add a highly motivated Research Associate to our fast moving, roll-up your sleeves team environment. Hub Langenfeld, Accelerate
CAMBRIDGE, Mass. The securities are only available to, and any invitation,
Position, Position
Furthermore, where permissible, we may charge for this service. Headquarters, Dominican
PhD or MD in cancer biology, immunology, genomics, biochemistry, or molecular/cellular biologybackground in immunology and immuno-oncology biomarker development strongly preferred. INFORMATION FROM CHILDREN UNDER 13 YEARS OF AGE. Dialogue, UN Global
prohibited or restricted. Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. HR Trainee Program, International
Arabia, South
Bayers leadership in agriculture provides tailored solutions
The online community has not agreed on what actions, if any, should be taken by the websites that receive the do not track signal, and therefore Do-Not-Track is not yet standardized. available on the website of the Luxembourg Stock Exchange (www.bourse.lu). Drs. Bayer, Meet
About. Audit, International
buy
Phone: +49 30 468 1111, Alfred-Nobel-Str. Due to legal reasons, the following content is only available for specialized journalists. The effective date of these Terms is May 18, 2022. There will be no public
Governance, Sustainability
High 61F. - NextPoint Therapeutics, a Cambridge, Mass.-based immuno-oncology development company, raised $80 million in Series B funding. NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi.. Community, Bayer
Our innovative approach integrates foundational. Audio, electronic, visual, thermal, olfactory or similar information, We generally do not collect this type of information, Inferences drawn from other Personal Information. The securities referred to herein will not be registered under the U.S. Securities Act of 1933, as
616 followers 500+ connections. Please be advised that you may not be able to opt-out of receiving certain service or transactional messages from us, including legal notices and certain communications related to the provision of the Site. Updates, Management &
He is currently CEO of portfolio company NextPoint Therapeutics and is also a board member of portfolio company iTeos Therapeutics (NASDAQ: ITOS). Freemans and Zangs independent discovery and characterization of the HHLA2 pathway formed the basis of the NextPoint approach. Human
we
Proc Natl Acad Sci U S A. If you would like to stop receiving newsletters or other marketing or promotional messages, notifications, or updates, you may do so by following the unsubscribe instructions that appear in these e-mail communications. Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Cookies can remember login information, preferences, and similar information. The company offers to build a broad strategic pipeline of first-in-class immunotherapies based on a novel, validated checkpoint axis, expanding the potential of immunotherapy. jurisdiction. Read more about our economic, ecological and social challenges and opportunities. Safety, Science
If you are not permitted to view materials on this webpage or are in any doubt as to whether you are
A browser sends cookies to a server when the browser makes a connection to the server (for example, when requesting a web page from the same domain that created the cookie). Any person who wishes to view these materials must first satisfy themselves that they are
Leaps by Bayer and Sanofi Ventures led the round for the Cambridge, Massachusetts-based company. This announcement is an advertisement and does not, under any circumstances, constitute a public
Our innovative approach integrates foundational. "We've been profitable and self-funded for 20 years. About Sanofi VenturesSanofi Ventures is the corporate venture capital arm of Sanofi. Authority, Saudi
Access to electronic versions of these materials is being made
Information, Analyst
Bayer Global
Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. The company and its founders have shown in preclinical models and with analysis of existing clinical datasets that the HHLA2 pathway is an important tumor-suppressive mechanism in many patients1,2. 24. In addition to the rights listed below, you have the right to not be discriminated against for exercising your rights. Science, Business
Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology.